HC Wainwright Has Positive Outlook of ETON FY2027 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at HC Wainwright increased their FY2027 earnings estimates for Eton Pharmaceuticals in a research note issued to investors on Monday, January 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $1.27 per share for the year, up from their prior forecast of $1.25. HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2028 earnings at $1.62 EPS and FY2029 earnings at $2.31 EPS.

Separately, Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON opened at $11.99 on Wednesday. The stock has a market cap of $312.35 million, a PE ratio of -54.50 and a beta of 1.38. The firm has a 50-day moving average of $11.51 and a 200-day moving average of $7.28. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $15.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Westside Investment Management Inc. boosted its position in shares of Eton Pharmaceuticals by 5.7% in the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock valued at $3,711,000 after acquiring an additional 33,275 shares during the period. Geode Capital Management LLC raised its stake in Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after purchasing an additional 32,365 shares in the last quarter. Jane Street Group LLC acquired a new stake in Eton Pharmaceuticals in the 3rd quarter worth about $90,000. Parkman Healthcare Partners LLC boosted its holdings in Eton Pharmaceuticals by 2.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after purchasing an additional 7,029 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $54,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.